Skip to Content

'
Jeffrey S. Morris, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Statistics, Division of Quantitative Sciences, Texas A & M University, College Station, TX

Bio Statement

 For additional information and access to published papers and  software click  here.

 

Research Interests

  • Functional data analysis
  • Proteomics
  • Bayesian methods
  • Missing data procedures
  • Wavelets

Education & Training

Degree-Granting Education

2000 Texas A&M University, College Station, TX, PHD, Statistics
1997 Texas A&M University, College Station, TX, MS, Statistics
1993 Messiah College, Grantham, PA, BS, Mathematics Education

Experience/Service

Academic Appointments

Research Assistant, Nutrition Group, Texas A&M University, College Station, TX, 1998-2000
Research Assistant, Department of Biostatistics, Texas A&M University, College Station, TX, 1996-1998

Honors and Awards

2003 Best Presentation, 4th Critical Assessment of Microarray Data Analysis (CAMDA)
2001 Travel Award for Young Investigators, Biometrics Section of ASA
2001 Visiting Fellowship, UK Engineering and Physical Sciences Research Council
1995 Graduate Merit Fellowship, Texas A&M University
1995 Science Dean's Graduate Fellowship, Texas A&M College

Professional Memberships

American Association for the Advancement of Science
Member, 2005-present
International Chinese Statistical Association
Member, 2005-present
International Society of Bayesian Analysis
Member, 2002-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Kamat P, Wen S, Morris JS, and Anandasabathy S. Barrett's and increasing BMI: A systematic review and meta-analysis. Annals of Surgery. In Press.
2. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 4/2/2013. PMCID: PMC3619157.
3. Zhu H, Brown PJ, Morris JS. Robust classification of functional and quantitative image data using functional mixed models. Biometrics. e-Pub 6/2012. PMCID: PMC3443537.
4. Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Effects of Gut-Targeted 15-LOX-1 Transgene Expression on Colonic Tumorigenesis in Mice. J Natl Cancer Inst 104(9):709-16, 5/2/2012. e-Pub 4/2/2012. PMCID: PMC3341308.
5. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 82(2):67-74, 2012. e-Pub 2/7/2012. PMID: 22327795.
6. Hrafnkelsson B, Morris JS, Baladandayuthapani V. Spatial Modeling of Annual Minimum and Masximum Teperature in Iceland. Meteorology and Atmospheric Physics 116(1-2):43-61, 2012.
7. Morris JS. Statistical Methods for Proteomic Biomarker Discovery Using Feature Extraction or Functional Data Analysis Approaches. Statistics and its Interface 5(1):117-136, 2012.
8. Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I. Title Mechanistic Contribution of Ubiquitous 15-Lipoxygenase-1 Expression Loss in Cancer Cells to Terminal Cell Differentiation Evasion. Cancer Prev Res (Phila) 4(12):1961-72, 12/2011. e-Pub 8/31/2011. PMCID: PMC3232310.
9. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-9, 10/10/2011. e-Pub 9/12/2011. PMCID: PMC3189091.
10. Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Bennett B, Abbruzzese JL, Wolff RA. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 68(6). e-Pub 4/2011. PMID: 21479635.
11. Morris JS, Baladandayuthapani V, Herrick RC, Sanna P, Gutstein H. Automated Analysis of Quantitative Image Data Using Isomorphic Functional Mixed Models, with Application to Proteomics Data. Ann Appl Stat 5(2A):894-923, 1/2011. PMCID: PMC3298181.
12. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. Oncology 80(5-6):373-81, 2011. e-Pub 8/3/2011. PMCID: PMC3171278.
13. Sabath N, Morris JS, Grauer D. Is there a twelfth protein-coding gene in the genome of influenza A? A selection-based approach to the detection of overlapping genes in closely related sequences. Journal of Molecular Evolution 73:305-315, 2011.
14. Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC. Reproducibility of SELDI spectra across time and laboratories. Cancer Inform 10(10):45-64, 2011. e-Pub 3/14/2011. PMCID: PMC3085423.
15. Zhu H, Brown PJ, Morris JS. Robust, Adaptive Functional Regression in Functional Mixed Model Framework. JASA 106(495):1167-1179, 2011.
16. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. e-Pub 12/14/2010. PMCID: PMC3066286.
17. Baladandayuthapani V, Ji Y, Talluri R, Nieto-Barajas LE, Morris JS. Bayesian Random Segmentation Models to Identify Shared Copy Number Aberrations for Array CGH Data. JASA 105(492):1358-1375, 12/2010. PMCID: PMC3079218.
18. Dowsey AW, English JA, Lisacek F, Morris JS, Yang GZ, Dunn MJ. Image analysis tools and emerging algorithms for expression proteomics. Proteomics 10(23):4226-57, 12/2010. PMID: 21046614.
19. Katz RL, He W, Khanna A, Fernandez RL, Zaidi TM, Krebs M, Caraway NP, Zhang HZ, Jiang F, Spitz MR, Blowers DP, Jimenez CA, Mehran RJ, Swisher SG, Roth JA, Morris JS, Etzel CJ, El-Zein R. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res 16(15):3976-87, 8/1/2010. e-Pub 7/22/2010. PMCID: PMC2949278.
20. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila) 3(7):829-38, 7/2010. e-Pub 6/22/2010. PMCID: PMC2900425.
21. Malloy EJ, Morris JS, Adar SD, Suh H, Gold DR, Coull BA. Wavelet-based functional linear mixed models: an application to measurement error-corrected distributed lag models. Biostatistics 11(3):432-52, 7/2010. e-Pub 2/15/2010. PMCID: PMC2883305.
22. Morris JS, Clark BN, Wei W, Gutstein HB. Evaluating the Performance of New Approaches to Spot Quantification and Differential Expression in 2-Dimensional Gel Electrophoresis Studies. J Proteome Res 9(1):595-604, 1/2010. e-Pub 12/2009. PMCID: PMC2802214.
23. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 1/2010. e-Pub 12/2009. PMCID: PMC2815707.
24. Dowsey AW, Morris JS, Gutstein HB, Yang GZ. Informatics and statistics for analyzing 2-d gel electrophoresis images. Methods Mol Biol 604:239-55, 2010. PMID: 20013375.
25. Cradock AL, Melly SJ, Allen JG, Morris JS, Gortmaker SL. Youth destinations associated with objective measures of physical activity in adolescents. J Adolesc Health 45(3 Suppl):S91-8, 9/2009. PMID: 19699443.
26. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553-62, 6/2009. PMCID: PMC2760963.
27. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 6/2009. e-Pub 1/2009. PMID: 19164203.
28. Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 144(3):216-21, 3/2009. PMID: 19289659.
29. Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene 28(12). e-Pub 2/2009. PMID: 19198625.
30. Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg 87(2):655-62, 2/2009. PMID: 19161814.
31. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. J Clin Oncol 27(6):843-50, 2/2009. e-Pub 1/2009. PMID: 19139433.
32. Li D, Suzuki H, Liu B, Morris J, Liu J, Okazaki T, Li Y, Chang P, Abbruzzese JL. DNA repair gene polymorphisms and risk of pancreatic cancer. Clin Cancer Res 15(2):740-6, 1/2009. PMCID: PMC2629144.
33. Zuo X, Peng Z, Moussalli MJ, Morris JS, Boraddus RR, Fischer SM, and Shureiqi I. Targeted PPAR-δ generic disruption profoundly inhibits colon tumorigenesis. JNCI 101(10):762-767, 2009. PMID: Not in Pub Med.
34. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
35. Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem 283(46):31341-7, 9/2008. e-Pub 9/2008. PMCID: PMC2581547.
36. Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J 22(6):1981-92, 6/2008. e-Pub 1/2008. PMCID: PMC2410033.
37. Morris JS, Brown PJ, Herrick RC, Baggerly KA, Coombes KR. Bayesian analysis of mass spectrometry proteomic data using wavelet-based functional mixed models. Biometrics 64(2):479-89, 6/2008. e-Pub 9/2007. PMCID: PMC2659628.
38. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy ML, Abbruzzese JL, Li D. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 29(6):1184-91, 6/2008. PMCID: PMC2443278.
39. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris J, Issa JP, Yuen ST, Leung SY, Hamilton SR. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 14(9):2560-9, 5/1/2008. PMID: 18451217.
40. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16(5):886-92, 5/2008. e-Pub 3/2008. PMCID: PMC2377397.
41. Morris JS, Clark BN, Gutstein HB. Pinnacle: a fast, automatic and accurate method for detecting and quantifying protein spots in 2-dimensional gel electrophoresis data. Bioinformatics 24(4). e-Pub 1/2008. PMID: 18194961.
42. Gutstein HB, Morris JS, Annangudi SP, Sweedler JV. Microproteomics: Analysis of protein diversity in small samples. Mass Spectrom Rev 27(4):316-30, Jul-Aug, 2008. PMCID: PMC2743962.
43. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-95, 9/1/2007. PMID: 17636525.
44. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong BC, Lam SK. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 298(12):1412-9, 9/2007. PMID: 17895457.
45. Cradock AL, Melly SJ, Allen JG, Morris JS, Gortmaker SL. Characteristics of school campuses and youth physical activity: Does size matter? Am J Prev Med 33(2):106-113, 8/2007. PMID: 17673097.
46. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. A phase II study of Erlotinib (OSI 774) in patients with unresectable hepatocellular carcinoma. Cancer 110(5):1059-67, 7/2007. PMID: 17623837.
47. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SM. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J 21(3):743-753, 3/2007. PMID: 17167069.
48. Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 109(4):668-674, 2/2007. e-Pub 1/2007. PMID: 17211862.
49. Karpievitch YV, Hill EG, Smolka AJ, Morris JS, Coombes KR, Baggerly KA, Almeida JS. PrepMS: TOF MS data graphical preprocessing tool. Bioinformatics 23(2):264-5, 1/2007. e-Pub 11/2006. PMCID: PMC2633108.
50. Song JJ, Lee HJ, Morris JS, Kang S. Clustering of time-course gene expression data using functional data analysis. Comput Biol Chem 31(4):265-74, 2007. PMID: 17631419.
51. Gutstein HB, Morris JS. Laser capture sampling and analytical issues in proteomics. Expert Rev Proteomics 4(5):627-37, 2007. PMCID: PMC2639751.
52. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66(3):762-71, 11/1/2006. PMID: 17011451.
53. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107(7):1475-82, 10/1/2006. PMID: 16944539.
54. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29(3):232-9, 6/2006. PMID: 16755175.
55. Mayo MS, Gajewski BJ, Morris JS. Some statistical issues in microarray gene expression data. Radiat Res 165(6):745-8, 6/2006. PMID: 16802876.
56. Morris JS, Carroll RJ. Wavelet-based functional mixed models. J R Stat Soc Series B Stat Methodol 68(2):179-199, 4/2006. PMCID: PMC2744105.
57. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25(8):1225-41, 2/2006. PMID: 16288226.
58. Morris JS, Arroyo C, Coull B, Ryan LM, Herrick R, Gortmaker SL. Using Wavelet-Based Functional Mixed Models to Characterize Population Heterogeneity in Accelerometer Profiles: A Case Study. JASA 101:1352-1364, 2006. PMID: Not in Pub Med.
59. Morris JS, Carroll RJ. Wavelet-Based Functional Mixed Models. Journal of the Royal Statistical Society, Series B 68:179-99, 2006. PMID: Not in Pub Med.
60. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 65(24):11486-92, 12/2005. PMID: 16357157.
61. Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, Kuerer HM. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 5(16):4107-17, 11/2005. PMID: 16254928.
62. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-6, 10/15/2005. PMID: 16118804.
63. Morris JS, Coombes KR, Koomen J, Baggerly KA, Kobayashi R. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics 21(9):1764-75, 5/2005. PMID: 15673564.
64. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166(4):1069-75, 4/2005. PMID: 15793287.
65. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103(7):1347-55, 4/2005. PMID: 15719440.
66. Coombes KR, Koomen JM, Baggerly KA, Morris JS, Kobayashi R. Understanding the characteristics of mass spectrometry data through the use of simulation. Cancer Informatics 1:41-52, 4/2005. PMID: Not in Pub Med.
67. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling: A young technology begins to mature. Nat Biotechnol 23(3):291-2, 3/2005. PMID: 15765078.
68. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-44, 2/20/2005. PMID: 15718321.
69. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. JNCI 97(4):307-9, 2/2005. PMID: 15713966.
70. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 3(4):322-31, 2/2005. PMID: 15814023.
71. Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A, Wallace MJ, Morello FA, Ahrar K, Murthy R, Lunagomez S, Hicks ME, Vauthey JN. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 16(2 Pt 1):215-25, 2/2005. PMID: 15713922.
72. Baggerly KA, Coombes KR, Morris JS. Bias, randomization, and ovarian proteomic data: A reply to 'Producers and Consumers'. Cancer Informatics 1:9-14, 2005. PMID: Not in Pub Med.
73. Baggerly KA, Deng L, Morris JS, Aldaz CM. Overdispersed logistic regression for SAGE: modeling multiple groups and covariates. BMC Bioinformatics 5:144, 10/2004. PMCID: PMC524524.
74. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22(14):2774-80, 7/15/2004. PMID: 15254045.
75. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100(11):2347-54, 6/1/2004. PMID: 15160337.
76. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Stephens LC. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920-7, 6/2004. PMID: 15184247.
77. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20(5):777-85, 3/2004. e-Pub 1/2004. PMID: 14751995.
78. Marron JS, Mueller HG, Rice J, Wang JL, Wang N, Wang Y, Coull B, Fahrmeier L, Guo W, Hall P, Harezlak J, Huang J, Kneip A, Lin X, Morris JS, Pourmadi M, Stadenmayer J, Wu C, Zhang D, Zhang H, and Zhao Y. Discussion of nonparametric and semiparametric regression. Statistica Sinica 14(3):615-621, 2004. PMID: Not in Pub Med.
79. Baggerly KA, Edmonson S, Morris JS, Coombes KR. High-Resolution Serum Proteomic Patterns for Ovarian Cancer Detection. Endocrine Related Cancers 11:583-584, 2004. PMID: Not in Pub Med.
80. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10(9):1059-69, 11/2003. PMID: 14597445.
81. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R, Sondak VK. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 98(8):1716-26, 10/2003. PMID: 14534889.
82. Coombes KR, Fritsche HA, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 49(10):1615-23, 10/2003. PMID: 14500586.
83. Baggerly KA, Morris JS, Wang J, Gold D, Xiao LC, Coombes KR. A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 3(9):1667-72, 9/2003. PMID: 12973722.
84. Morris JS, Baggerly KA, Coombes KR. Bayesian shrinkage estimation of the relative abundance of mRNA transcripts using SAGE. Biometrics 59(3):476-86, 9/2003. PMID: 14601748.
85. Baggerly KA, Deng L, Morris JS, Aldaz CM. Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics 19(12):1477-83, 8/2003. PMID: 12912827.
86. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100(17):9968-73, 8/2003. PMID: 12909723.
87. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness: A study in 26 patients. Radiology 227(1):251-60, 4/2003. PMID: 12616006.
88. Switzer KC, McMurray DN, Morris JS, Chapkin RS. (n-3) Polyunsaturated fatty acids promote activation-induced cell death in murine T lymphocytes. J Nutr 133(2):496-503, 2/2003. PMID: 12566490.
89. Hong MY, Chapkin RS, Davidson LA, Turner ND, Morris JS, Carroll RJ, Lupton JR. Fish Oil Enhances Targeted Apoptosis During Colon Tumor Initiation In Part by Downregulating BCL-2. Nutr Cancer 46(1):44-51, 2003. PMID: 12925303.
90. Morris JS, Vannucci M, Brown PF, Carroll RJ. Rejoinder to Wavelet-Based Nonparametric Modeling of Hierarchical Functions in Colon Carcinogenesis. JASA 98:591-597, 2003. PMID: Not in Pub Med.
91. Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY, Carroll RJ. Understanding the relationship between carcinogen-induced DNA adduct levels in distal and proximal regions of the colon. Adv Exp Med Biol 537:105-16, 2003. PMID: 14995031.
92. Morris JS, Vannucci M, Brown PH, Carroll RJ. Wavelet-Based Nonparametric Modeling of Hierarchical Functions in Colon Carcinogenesis. JASA 98:573-583, 2003.
93. Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong M, Carroll RJ. A Bayesian analysis of colonic crypt structure and coordinated response to carcinogen exposure incorporating missing crypts. Biostatistics 3(4):529-46, 12/2002. PMID: 12933596.
94. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 16(12 Suppl No 14):31-7, 12/2002. PMID: 12520638.
95. Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 160(2):529-36, 2/2002. PMCID: PMC1850645.
96. Morris JS. The BLUPs Are Not "Best" When It Comes To Bootstrapping. Statistics and Probability Letters 56:425-430, 2002.
97. Hong MY, Chapkin RS, Morris JS, Wang N, Carroll RJ, Turner ND, Chang WC, Davidson LA, Lupton JR. Anatomical site-specific response to DNA damage is related to later tumor development in the rat azoxymethane colon carcinogenesis model. Carcinogenesis 22(11):1831-5, 11/2001. PMID: 11698346.
98. Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR. CpG island methylation in colorectal adenomas. Am J Pathol 159(3):1129-35, 9/2001. PMCID: PMC1850474.
99. Shureiqi I, Cooksley CD, Morris J, Soliman AS, Levin B, Lippman SM. Effect of age on risk of second primary colorectal cancer. J Natl Cancer Inst 93(16):1264-6, 8/2001. PMID: 11504772.
100. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 61(12):4879-84, 6/2001. PMID: 11406566.
101. Arrington JL, Chapkin RS, Switzer KC, Morris JS, McMurray DN. Dietary n-3 Polyunsaturated Fatty Acids Modulate Purified Murine T-cell Subset Activation. Clin Exp Immunol 125(3):499-507, 2001. PMID: 11531960.
102. Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY, Carroll RJ. Parametric and Nonparametric Methods for Understanding the Relationship Between Carcinogen-Induced DNA Adduct Levels in Distal and Proximal Regions of the Colon. JASA 96:816-826, 2001. PMID: Not in Pub Med.
103. Hong MY, Lupton JR, Morris JS, Wang N, Carroll RJ, Davidson LA, Elder RH, Chapkin RS. Dietary fish oil reduces O6-methylguanine DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. Cancer Epidemiol Biomarkers Prev 9(8):819-26, 8/2000. PMID: 10952099.
104. Davidson LA, Brown RE, Chang WC, Morris JS, Wang N, Carroll RJ, Turner ND, Lupton JR, Chapkin RS. Morphodensitometric analysis of protein kinase C beta(II) expression in rat colon: modulation by diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis 21(8):1513-9, 8/2000. PMID: 10910952.
105. Hong MY, Chapkin RS, Wild CP, Morris JS, Wang N, Carroll RJ, Turner ND, Lupton JR. Relationship between DNA adduct levels, repair enzyme, and apoptosis as a function of DNA methylation by azoxymethane. Cell Growth Differ 10(11):749-58, 11/1999. PMID: 10593651.

Invited Articles

1. Morris JS. Member's Discoveries: Fatal flaws in cancer research. IMS Bulletin 39(1):5, 2010.
2. Morris JS. Statistical Issues in Proteomic Research. Bulletin of the International Society for Bayesian Analysis 14(4):9-13, 2008.
Other Articles
1. Dowsey AW, English JA, Lisacek F, Morris JS, Yang GZ, and Dunn MJ. Advance Article A22975: Image Analysis Tools in Proteomics. Encyclopedia of Life Sciences. John Wiley & Sons, Ltd. eScholar ID: 148685 DOI:10.1002/97804770015902.a0006216.pub2. e-Pub 2011.
2. Morris JS. Review of Wavelet Methods in Statistics with R. Biometrics 65(2):667-668, 2009.
3. Morris JS. Comment on sure independence screening for ultra-high dimensional feature space. Journal of the Royal Statistical Society Series B 70(5):900-901, 2008.

Abstracts

1. Lin E, Morris J, Crane C, Chau NK, Wolf R, Delcos M, Xiong X, Janjan N, Abbruzzese JL. Reduction of Hand and Foot Syndrome Symptoms in Patients with Metastatic Colorectal Cancer with Concurrent Use of Celecoxib. Proceedings of the American Society of Clinical Oncology 21:138b (#2364), 2003.
2. Kulkarni A, Gagneja H, Kaw M, Roquemore J, Morris J. Does Concurrent EGD and Colonoscopy Subject Patients to a Higher Risk of Procedure Related Adverse Events? . American Journal of Gastroenterology:S242, 9/2002.
3. Lin E, Morris, J, Crane, C, Chau, NK, Wolf, R, Delcos, M, Xiong, X, Janjan, N, Abbruzzese JL. Celecoxib Attenuated Capecitabine-induced Hand-and-foot Syndrome (HFS) and Diarrhea and Improved Time to Tumor Progression in Metastatic Colorectal Cancer (mCRC). ASCO, 2002.
4. Patel MB, Kaw M, Gagneja H, Cohen D, Morris J, Singh S, Ho L, Ajani J. Endoscopic Ultrasonography for Restaging of Gastric Adenocarcinoma. GI Endoscopy 55(5):AB251, 2002.
5. Abu-Hamda E, Kaw M, Gagneja H, Wolff RA, Cohen D, Morris J, Pisters P, Lee J, Vauthey J-N, Evans D. Endoscopic Ultrasound (EUS) in the Staging of Pancreatic Adenocarcinoma and Detection of Small Tumors. GI Endoscopy 55:AB240, 2002.

Book Chapters

1. Morris JS, Wu C, Coombes KR, Baggerly KA, Wang J, Zhang L. Alternative Probeset Definitions for Combining Microarray Data Across Studies Using Different Versions of Affymetrix Oligonucleotide Arrays. In: Meta-Analysis in Genetics. Ed(s) Guerra R, Allison D. Chapman-Hall. In Press.
2. Crainiceanu CM, Caffo BS, and Morris JS. Multilevel Functional Data Analysis. In: SAGE Handbook for Multilevel Modeling. In Press.
3. Morris JS, Baggerly KA, Gutstein HB, Coombes KR. Statistical contributions to proteomic research. In: Methods Mol Biol. 641. Humana, 143-66, 2010. ISBN: 20407946.
4. Coombes, KR, Baggerly KA, and Morris JS. Pre-Processing Mass Spectrometry Data. In: Fundamentals of Data Mining in Genomics and Proteomics. Ed(s) Dubitzky W, Granzow M, Berrar D. Kluwer: Boston, 79-99, 2007.
5. Baggerly KA, Coombes KR, Morris JS. An Introduction to High-Throughput Bioinformatics Data. In: Bayesian Inference for Gene Expression and Proteomics. Ed(s) KA Do, P Mueller, and M Vannucci. Cambridge University Press, 2006.
6. Morris JS, Brown PJ, Baggerly KA, Coombes KR. Bayesian Inference for Gene Expression and Proteomics. In: Analysis of Mass Spectrometry Data Using Bayesian Wavelet-Based Functional Mixed Models. Ed(s) KA Do, P Mueller, M Vannucci, 2006.
7. Guindani M, Do KA, Muller P, Morris JS. Bayesian Mixture Models for Gene Expression and Protein Profiles. In: Bayesian Inference for Gene Expression and Proteomics. Ed(s) KA Do, P Mueller, M Vannucci. Cambridge University Press, 2006.
8. Morris J. Shrinkage Estimation for SAGE Data using a Mixture Dirichlet Prior. In: Bayesian Inference for Gene Expression and Proteomics. Ed(s) KA Do, P Mueller, M Vannucci. Cambridge University Press, 2006.
9. Hu J, Yin G, Morris JS, Zhang L, Wright FA. Entropy and Survival-based Weights to Combine Affymetrix Array Types in the Analysis of Differential Expression and Survival. In: Methods of Microarray Data Analysis IV. Springer-Verlag, 95-108, 2005.
10. Morris JS, Yin G, Baggerly KA, Wu C, Zhang L. Pooling Information Across Different Studies and Oligonucleotide Microarray Chip Types to Identify Prognostic Genes for Lung Cancer. In: Methods of Microarray Data Analysis IV. Springer-Verlag, 51-56, 2005.

Grant & Contract Support

Title: UT MD Anderson Cancer Center Community Clinical Oncology Program Research Base
Funding Source: NIH/NCI
Role: Program Leader
Principal Investigator: Michael Fisch
Duration: 8/13/2012 - 5/31/2015
 
Title: CERCIT: Comparative Effectiveness Research on Cancer in Texas (P04)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Linda S Elting
Duration: 8/1/2010 - 7/31/2013
 
Title: Proteomic Approaches to Alcoholism
Funding Source: NIH/NIAAA
Role: Co-Principal Investigator
Principal Investigator: Howard B. Gutstein
Duration: 9/30/2005 - 8/31/2008
 
Title: Molecular Targeting of 15-Lipoxygenase-1 Colon Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Imad Shureiqi
Duration: 8/1/2004 - 11/30/2008

Last updated: 8/27/2013